JP2020528744A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528744A5 JP2020528744A5 JP2019571213A JP2019571213A JP2020528744A5 JP 2020528744 A5 JP2020528744 A5 JP 2020528744A5 JP 2019571213 A JP2019571213 A JP 2019571213A JP 2019571213 A JP2019571213 A JP 2019571213A JP 2020528744 A5 JP2020528744 A5 JP 2020528744A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- subject
- composition
- cell
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 80
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 201000011510 cancer Diseases 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 9
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 230000021633 leukocyte mediated immunity Effects 0.000 claims description 5
- 210000000068 Th17 cell Anatomy 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 210000003289 regulatory T cell Anatomy 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 230000005809 anti-tumor immunity Effects 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 239000012620 biological material Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 244000309459 oncolytic virus Species 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523105P | 2017-06-21 | 2017-06-21 | |
| US62/523,105 | 2017-06-21 | ||
| PCT/US2018/038289 WO2018236870A2 (en) | 2017-06-21 | 2018-06-19 | METHODS AND COMPOSITIONS FOR TARGETING CANCER CELLS WITH A CHIMERIC ANTIGENIC RECEPTOR |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020528744A JP2020528744A (ja) | 2020-10-01 |
| JP2020528744A5 true JP2020528744A5 (OSRAM) | 2021-07-29 |
| JP7352473B2 JP7352473B2 (ja) | 2023-09-28 |
Family
ID=64691428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019571213A Active JP7352473B2 (ja) | 2017-06-21 | 2018-06-19 | がん細胞を標的化するキメラ抗原受容体のための方法および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10233226B2 (OSRAM) |
| EP (2) | EP3642344B1 (OSRAM) |
| JP (1) | JP7352473B2 (OSRAM) |
| CN (1) | CN111386347B (OSRAM) |
| AU (2) | AU2018289428B2 (OSRAM) |
| CA (1) | CA3068256A1 (OSRAM) |
| DK (1) | DK3642344T3 (OSRAM) |
| ES (1) | ES3014942T3 (OSRAM) |
| FI (1) | FI3642344T3 (OSRAM) |
| WO (1) | WO2018236870A2 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3068256A1 (en) * | 2017-06-21 | 2018-12-27 | The University Of North Carolina At Chapel Hill | Methods and compositions for chimeric antigen receptor targeting cancer cells |
| AU2020217868A1 (en) * | 2019-02-08 | 2021-08-12 | Biontech Cell & Gene Therapies Gmbh | Chimeric antigen receptor-modified cells for the treatment of CLDN6-expressing cancers |
| CN109880804B (zh) * | 2019-03-06 | 2022-07-15 | 徐州医科大学 | 一种靶向b7h3的car-t细胞的制备方法及应用 |
| CN109929039A (zh) * | 2019-03-28 | 2019-06-25 | 郑州大学第一附属医院 | 基于cd276抗体的嵌合抗原受体、慢病毒表达载体及其应用 |
| CN112390892B (zh) * | 2019-08-14 | 2024-01-12 | 博源润生医药（杭州）有限公司 | 一种嵌合抗原受体以及表达该嵌抗原受体的免疫效应细胞 |
| CN114929748A (zh) * | 2019-11-18 | 2022-08-19 | 得克萨斯州大学系统董事会 | 抗b7-h3单克隆抗体及其使用方法 |
| EP4106805A4 (en) * | 2020-02-20 | 2024-07-03 | Win Therapeutics, Inc. | Bispecific gd2 and b7h2 binding molecules and methods of use |
| WO2021207171A1 (en) * | 2020-04-06 | 2021-10-14 | St. Jude Children's Research Hospital, Inc. | B7-h3 chimeric antigen receptors |
| CN111944050B (zh) * | 2020-08-19 | 2022-05-13 | 苏州普乐康医药科技有限公司 | 一种抗b7-h3抗体及其应用 |
| WO2022098925A1 (en) * | 2020-11-04 | 2022-05-12 | Fate Therapeutics, Inc. | Engineered ipsc and immune effector cells for heterogenous tumor control |
| CN113480668A (zh) * | 2020-12-14 | 2021-10-08 | 广州百暨基因科技有限公司 | 抗b7h3嵌合抗原受体及其应用 |
| CN114763381B (zh) * | 2021-01-13 | 2025-01-28 | 博生吉医药科技(苏州)有限公司 | B7-h3嵌合抗原受体修饰的t细胞及其应用 |
| WO2022241028A1 (en) * | 2021-05-11 | 2022-11-17 | The General Hospital Corporation | Methods for treating graft versus host disease |
| AU2022310862A1 (en) | 2021-07-14 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
| IL316032A (en) | 2022-04-08 | 2024-11-01 | Regeneron Pharma | Multicomponent receptor and signaling complexes |
| WO2024112880A1 (en) * | 2022-11-23 | 2024-05-30 | The University Of North Carolina At Chapel Hill | B7-h3 targeting ligands and methods of use |
| CN116699136B (zh) * | 2023-06-25 | 2026-03-17 | 郑州大学 | 一种用于胰腺导管腺癌早期筛查和诊断的血清蛋白标志物、应用和相应分析方法 |
| CN117025541B (zh) * | 2023-08-15 | 2025-10-17 | 福建医科大学附属协和医院 | 一种靶向b7-h3并共表达细胞因子和趋化因子的car-t细胞及其用途 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6207673B1 (en) | 1997-03-12 | 2001-03-27 | The University Of North Carolina At Chapel Hill | Covalent conjugates of topoisomerase I and topoisomerase II inhibitors |
| TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| US7435596B2 (en) * | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| WO2010045495A2 (en) | 2008-10-16 | 2010-04-22 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA2866126A1 (en) * | 2012-03-03 | 2013-09-12 | Immungene, Inc. | Engineered antibody-interferon mutant fusion molecules |
| US9790282B2 (en) | 2013-03-25 | 2017-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD276 polypeptides, proteins, and chimeric antigen receptors |
| WO2015179801A1 (en) * | 2014-05-23 | 2015-11-26 | University Of Florida Research Foundation, Inc. | Car based immunotherapy |
| MY181834A (en) * | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| EP3193933B1 (en) | 2014-09-17 | 2021-04-28 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Anti-cd276 antibodies (b7h3) |
| KR20180004740A (ko) * | 2015-04-20 | 2018-01-12 | 이펙터 테라퓨틱스, 인크. | 암 및 감염 치료에 사용하기 위한 면역 체크포인트 조절 인자의 억제제 |
| US10562952B2 (en) | 2015-09-10 | 2020-02-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD276 chimeric antigen receptors |
| EP3359569A2 (en) | 2015-10-06 | 2018-08-15 | Alector LLC | Anti-trem2 antibodies and methods of use thereof |
| CA3068256A1 (en) * | 2017-06-21 | 2018-12-27 | The University Of North Carolina At Chapel Hill | Methods and compositions for chimeric antigen receptor targeting cancer cells |
-
2018
- 2018-06-19 CA CA3068256A patent/CA3068256A1/en active Pending
- 2018-06-19 FI FIEP18821448.0T patent/FI3642344T3/fi active
- 2018-06-19 CN CN201880048944.2A patent/CN111386347B/zh active Active
- 2018-06-19 WO PCT/US2018/038289 patent/WO2018236870A2/en not_active Ceased
- 2018-06-19 ES ES18821448T patent/ES3014942T3/es active Active
- 2018-06-19 EP EP18821448.0A patent/EP3642344B1/en active Active
- 2018-06-19 EP EP24217264.1A patent/EP4548927A3/en active Pending
- 2018-06-19 DK DK18821448.0T patent/DK3642344T3/da active
- 2018-06-19 JP JP2019571213A patent/JP7352473B2/ja active Active
- 2018-06-19 US US16/012,432 patent/US10233226B2/en active Active
- 2018-06-19 AU AU2018289428A patent/AU2018289428B2/en active Active
-
2019
- 2019-01-30 US US16/262,490 patent/US10519214B2/en active Active
- 2019-12-30 US US16/730,951 patent/US20200369743A1/en not_active Abandoned
-
2024
- 2024-09-24 AU AU2024220000A patent/AU2024220000A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3131017C (en) | Immunostimulatory bacteria modified to colonize tumors, tumor-resident immune cells, and the tumor microenvironment | |
| Han et al. | Ferritin protein cage nanoparticles as versatile antigen delivery nanoplatforms for dendritic cell (DC)-based vaccine development | |
| JP2021523110A (ja) | 遺伝子発現のためのナノ粒子及びその使用 | |
| JP2022524018A (ja) | Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法 | |
| BR112020018670A2 (pt) | Receptor de antígeno quimérico de receptor alfa 2 da il-13 (il13ra2) para imunoterapia com células t específicas para tumor | |
| WO2019080538A1 (zh) | 嵌合抗原受体、其修饰的NK细胞、编码 DNA、mRNA、表达载体、制备方法和应用 | |
| WO2021216738A2 (en) | Compositions and methods of generating an immune response | |
| CN111544585B (zh) | 一种可助推免疫细胞在体内扩增的佐剂 | |
| US20170183667A1 (en) | Heterogeneous polypeptide expression cassette | |
| WO2023081109A1 (en) | Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases | |
| WO2020112815A1 (en) | Anti-lmp2 tcr-t cell therapy for the treatment of ebv-associated cancers | |
| JP2021521847A (ja) | 活性化された病原性ｔ細胞およびｎｋ細胞の選択的標的化のための自己／同種免疫防御受容体 | |
| JP2024133576A (ja) | アプタマーベースのｃａｒ ｔ－細胞スイッチ | |
| JP2023021131A (ja) | 免疫を調節するペプチド、ポリペプチド又は細胞を作製する方法 | |
| CN117777271B (zh) | 一种t细胞受体(tcr)及其用途 | |
| US20250025559A1 (en) | Irf-4 engineered t cells and uses thereof in treating cancer | |
| CN114249811A (zh) | 一种特异识别癌/睾丸抗原hca587/magec2的t细胞受体及其应用 | |
| WO2018201794A1 (zh) | 抗人cd19抗原的嵌合抗原受体及其应用 | |
| TW202118780A (zh) | Ｉｉ類ｍｈｃ分子及其使用方法 | |
| CN117777270B (zh) | 一种t细胞受体(tcr)及其用途 | |
| JP2023068126A (ja) | 標的細胞特異的に結合して多重免疫機能が強化されたキメラ抗原及びこの用途 | |
| CN113929767B (zh) | 具有高亲和力的t细胞受体及其用途 | |
| CN116655804A (zh) | 一种用于激活嵌合抗原受体效应细胞的中间模块分子及其应用 | |
| CN119486753A (zh) | 个体化癌症表位及其使用方法 | |
| US20240325441A1 (en) | Modified immune cell and use thereof |